Results 61 to 70 of about 20,522 (204)
Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels.
Sevinç KURBANOĞLU +6 more
doaj
A systematic review and meta‐analysis of 9 randomised controlled trials (67,662 patients) found that evolocumab significantly improved lipid parameters and reduced major adverse cardiovascular events, myocardial infarction, and coronary revascularisation.
Anika Goel +10 more
wiley +1 more source
The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia
Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk of coronary heart disease. Ezetimibe is the first member of a new class of selective cholesterol absorption inhibitors.
Suleiman Ehab S +2 more
doaj +1 more source
Enlicitide (MK‐0616), an oral macrocyclic peptidyl PCSK9 inhibitor, blocks the interaction between circulating PCSK9 and hepatic LDL receptors, enhancing LDL‐C clearance from the bloodstream. This systematic review and meta‐analysis of three randomized, double‐blind, placebo‐controlled trials (n = 3593) evaluated the efficacy and safety of enlicitide ...
Muhammad Farhan +10 more
wiley +1 more source
ABSTRACT Introduction Matrix stones are rare urinary calculi composed predominantly of organic matrix, with poorly understood pathogenesis. We herein report a case involving refractory matrix stones with longitudinal compositional changes and characterize the final specimen using histopathological and proteomic analyses. Case Presentation A 54‐year‐old
Yuki Hideo +4 more
wiley +1 more source
Abstract An 81‐year‐old man with a history of high‐grade urothelial carcinoma of the bladder and ureter on treatment with atezolizumab and tiragolumab presented to the emergency department with 5 months of malaise, generalized weakness, and fatigue and 2 weeks of subjective fevers. One month prior to presentation, he received an empiric 9‐day course of
Hadi Roudsari +4 more
wiley +1 more source
BackgroundRandomized clinical trials (RCTs) about Ezetimibe's efficacy on patient-oriented outcomes have given discordant results. The aim of this study was to determine the net effect of Ezetimibe and of the widely marketed combination, Ezetimibe ...
Alessandro Battaggia +4 more
doaj +1 more source
Background The utility of ezetimibe in preventing cardiovascular outcomes remains controversial. To guide future assessments of the effectiveness of ezetimibe in routine care, we evaluated how this medication has been prescribed to high-risk older adults
Kristin K. Clemens +3 more
doaj +1 more source
The important role of cholesterol in tumor metastasis has been widely studied in recent years. Ezetimibe is currently the only selective cholesterol uptake inhibitor on the market.
Lingkai Kong +6 more
doaj +1 more source
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia
Background Ezetimibe (Zetia®) is a potent inhibitor of cholesterol absorption that has been approved for the treatment of hypercholesterolemia. Statin, an inhibitor of cholesterol synthesis, is the first-choice drug to reduce low-density lipoprotein ...
Aoyama Naoyoshi +8 more
doaj +1 more source

